Sunday, October 09, 2016 12:07:50 AM
VWAP: 1.245 Total Vol: 1M
The support at 1.30 broke when the vol was around 250K. Stop loss raiding helped further depress the price.
Since the retail bulls have already loaded up, not many could have averaged down. So, some big guy might have loaded up 500K shares (totalVolume/2).
HTBX borrowed $7.5M (in 4 tranches: 1.5M, 1.5M, 2.25M, 2.25M).
http://www.bizjournals.com/triangle/news/2014/08/25/square-1-bank-lends-7-5m-to-durhams-heat-biologics.html
"As of September 30, 2015 we had drawn down three of the four Tranche Loans and expect to draw the last tranche by the end of the year."
"at the end of 2015 we had drawn down all four Tranche Loans for a total of $7.5 million."
Negative and positive covenants:
"
First Amendment: nothing to worry in this amendment, as htbx is in full compliance.
http://ir.heatbio.com/all-sec-filings/content/0001553350-15-000660/htbx_ex4z1.htm
Second Amendment:
https://biz.yahoo.com/e/160303/htbx8-k.html
http://ir.heatbio.com/all-sec-filings/content/0001553350-16-001670/0001553350-16-001670.pdf
A takeout from the second amendment:
"(i) on or before September 30, 2016, the Company shall have enrolled at least 18 patients in the Company’s DURGA (HS-110) clinical trial"
HTBX has fulfilled the above covenant on Sep 14, 2016:
http://www.heatbio.com/newsroom/press-releases/detail/531/heat-biologics-resumes-enrollment-in-its-non-small-cell
"Heat intends to complete enrollment of each of the two 9-patient cohorts consistent with the original design of the trial, with the potential to expand each cohort up to 30 patients. The topline data for additional patients enrolled in the trial are anticipated within the next twelve months.”
See what HTBX said before: "If we do not comply with the covenants under our secured loans with Square 1 Bank, we may be forced to seek other sources of
financing and if we default on our secured loan with Square 1 Bank we could be forced to suspend all operations.”
Since HTBX is in full compliance with all covenants, there is NO NEED for htbx to pay back 20% of the loan. Instead, they could just pay the interest rate. Add another dot to this picture: HTBX cancelled an offering.
On Friday, they came out with a PR: "while pursuing an AGGRESSIVE clinical program that will generate four IMPORTANT data readouts this quarter"
Given all these facts, why SP was depressed? When everything points to a positive direction, and the stock been in a consolidation phase for 25 trading days, SP lost 7% with 1M volume.
1M volume is not a significant volume because on 9/23 with closing price of 1.44 the volume was 1M. On the next trading day 9/26, the SP opened with 1.49, closed at 1.44 with 3M. So, 9/26 was a big day compared to 9/7.
If you are long, either HOLD or average down. There are lots of people who wanna buy around $1.00; and these sukers tell you to sell your holdings to depress the SP, so that they can join the wagon. Don't give in to that if you have done DD.
Recent NHWK News
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM